Expand TVTX Menu
TVTX MENU

TVTX Latest Press Releases

-- June 16, 2026 --

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 Business Wire 4:30 PM

-- June 11, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- June 4, 2026 --

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress Business Wire 10:09 AM

-- June 2, 2026 --

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases Business Wire 7:01 AM

-- May 27, 2026 --

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI (sparsentan) in IgA Nephropathy Business Wire 4:05 PM

-- May 12, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- May 7, 2026 --

Travere Therapeutics to Participate at Upcoming Investor Conferences Business Wire 4:30 PM

-- May 6, 2026 --

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes Business Wire 10:28 PM

-- May 5, 2026 --

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes Business Wire 4:01 PM

-- May 4, 2026 --

Travere Therapeutics Reports First Quarter 2026 Financial Results Business Wire 4:01 PM

-- April 27, 2026 --

Travere Therapeutics to Report First Quarter 2026 Financial Results Business Wire 4:30 PM

-- April 14, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS Globe Newswire 7:00 AM

-- April 13, 2026 --

Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the First and Only Approved Medicine for FSGS Business Wire 6:16 PM

-- February 19, 2026 --

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Business Wire 4:01 PM

-- February 12, 2026 --

Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results Business Wire 4:30 PM

-- February 11, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- February 4, 2026 --

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit Business Wire 4:30 PM

-- January 30, 2026 --

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm Globe Newswire 8:50 PM

-- January 28, 2026 --

TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm PRNewswire 7:10 AM

-- January 27, 2026 --

TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses Globe Newswire 7:54 AM

-- January 16, 2026 --

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm Business Wire 6:00 AM
Market Data Delayed 15 Minutes